Table 5.
US FDA-approved human mAbs
| No. | Antibody | Brandname | Company | Approval# | Target | References | Technology |
|---|---|---|---|---|---|---|---|
| 1 | Adalimumab | Humira | Abbott_Laboratories | 2002 | TNFα | den Broeder et al. [178] | Phage display |
| 2 | Panitumumab | Vectibix | Amgen | 2006 | EGFR | Tyagi et al. [179] | XenoMouse |
| 3 | Ustekinumab | Stelara | Johnson & Johnson | 2009 | IL-12 | Bartlett et al. [17] | HuMabMouse |
| 4 | Canakinumab | Ilaris | Novartis | 2009 | IL-1β | Church et al. [18] | HuMabMouse |
| 5 | Golimumab | Simponi | Johnson & Johnson/Merck | 2009 | TNFα | Zhou et al. [19] | HuMabMouse |
| 6 | Ofatumumab | Arzerra | GlaxoSmithKline (Genmab) | 2009 | CD20 | Coiffier et al. [20] | HuMabMouse |
| 7 | Denosumab | Prolia, Xgeva | Amgen | 2010 | RANKL | Reddy et al. [21] | XenoMouse |
| 8 | Belimumab | Benlysta | GlaxoSmithKline | 2011 | BCAF | Ding et al. [180] | Phage display |
| 9 | Ipilimumab | Yervoy | Bristol-Myers Squibb | 2011 | CTLA-4 | Morse et al. [22] | HuMabMouse |
| 10 | Ramucirumab | Cyramza | Eli Lilly (ImClone) | 2014 | VEGFR2 | Krupitskaya et al. [181] | Phage display |
| 11 | Nivolumab | Opdivo | Bristol-Myers Squibb | 2014 | PD-1 | Wolchok et al. [23] | HuMabMouse |
| 12 | Alirocumab | Praluent | Sanofi and Regeneron | 2015 | PCSK9 | Roth et al. [24] | Veloclmmune Mouse |
| 13 | Daratumumab | Darzalex | Johnson & Johnson (Genmab) | 2015 | CD38 | de Weers et al. [25] | HuMabMouse |
| 14 | Necitumumab | Portrazza | Eli Lilly (ImClone) | 2015 | EGFR | Kuenen et al. [182] | Phage display |
| 15 | Evolocumab | Repatha | Amgen | 2015 | PCSK9 | Hirayama et al. [26] | XenoMouse |
| 16 | Secukinumab | Cosentyx | Novartis | 2015 | IL-17α | Chioato et al. [27] | XenoMouse |
| 17 | Olaratumab | Lartruvo | Eli Lilly | 2016 | PDGFRα | Chiorean et al. [28] | HuMabMouse |
| 18 | Atezolizumab | Tecentriq | Roche | 2016 | PD-L1 | McDermott et al. [183] | Phage display |
| 19 | Avelumab | Bavencio | Pfizer | 2017 | PD-L1 | Boyerinas et al. [184] | Phage display |
| 20 | Brodalumab | Siliq | Valeant Pharmaceuticals | 2017 | IL-17R | Papp et al. [29] | XenoMouse |
| 21 | Dupilumab | Dupixent | Sanofi and Regeneron | 2017 | IL-4R | Wenzel et al. [30] | Veloclmmune Mouse |
| 22 | Durvalumab | Imfinzi | Medimmune/AstraZeneca | 2017 | PD-L1 | Antonia et al. [31] | XenoMouse |
| 23 | Guselkumab | Tremfya | Jassen Biotech | 2017 | IL-23 | Sofen et al. [185] | Phage display |
| 24 | Sarilumab | Kevzara | Sanofi and Regeneron | 2017 | IL-6R | Huizinga et al. [32] | Veloclmmune Mouse |
| 25 | Erenumab | Aimovig | Novartis and Amgen | 2018 | CGRPR | Tepper et al. [33] | XenoMouse |
| 26 | Cemiplimab | Libtayo | Regeneron | 2018 | PD-1 | Migden et al. [34] | Veloclmmune Mouse |
| 27 | Emapalumab | Gamifant | NovImmmune | 2018 | IFNγ | Al-Salama ZT [186] | Phage display |
| 28 | Moxetumomab pasudodox | Lumoxiti | MedImmune/AstraZeneca | 2018 | CD22 | Kreitman et al. [187] | Phage display |
#Year of the first US FDA approval